As the COVID-19 pandemic first surged across the country and around the world – impacting the nation’s economy, society and healthcare industry like never before – biotechnology and pharmaceutical companies quickly mobilized to combat the virus. While the first wave of vaccines and treatments entered the clinic for testing, hope for a quick solution was sparked and expectations were high. But as the coronavirus mutates and evolves, initial immunity may wane and early approaches may become obsolete or less effective. Hope for a long-term solution therefore may lie in the second or third generation of COVID-19 vaccines and therapies that took extra time to consider long-term need. This panel will feature experts and researchers pioneering innovative initiatives with the long game in mind.